Saturday, June 15, 2024

Ulcerative Colitis Treatment Expanded: Bausch Health Adds PrUCERIS® to More Public Drug Plans

Similar articles

Bausch Health, a subsidiary of Bausch Health Companies Inc., has announced an expansion in the availability of PrUCERIS® (budesonide) aerosol foam for treating mild to moderate distal ulcerative colitis in adults. This expansion includes additional listings on several Canadian public drug plans, further enhancing accessibility for patients.

UCERIS is now available under the public drug plans of Alberta, Prince Edward Island, and Newfoundland and Labrador. Additionally, it is accessible to beneficiaries of federal drug plans for Indigenous people through the Non-Insured Health Benefit (NIHB) and Veterans Affairs Canada. This follows earlier listings this year, which made UCERIS available through the public drug plans of Ontario, Quebec, Saskatchewan, New Brunswick, and Nova Scotia.

“We are very pleased that these further public drug plan listings for UCERIS mean more Canadians with distal ulcerative colitis now have access to this new therapy,” said Cees Heiman, Senior Vice-President, of Europe and Canada, Bausch Health. “It is encouraging that these public drug plans have moved quickly to finalize their listings after we agree in principle following negotiations with the pan-Canadian Pharmaceutical Alliance.”

Effective Remission Treatment for Distal Ulcerative Colitis Now Widely Available in Canada

UCERIS is part of Bausch Health’s growing gastrointestinal franchise and has been available by prescription in Canada since September 2023. It is also covered by the majority of private insurance drug plans in the country. UCERIS is the only glucocorticosteroid rectal foam available in Canada indicated for the induction of remission in adult patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge.

In clinical studies, UCERIS demonstrated significant effectiveness in inducing remission. A higher proportion of patients in the UCERIS group achieved remission at Week 6 compared to the placebo group, with significant reductions in rectal bleeding. Additionally, most patients (84%) preferred the foam formulation over the enema due to its better tolerability and easier application.

Ulcerative Colitis

UCERIS Approval and Expanded Listings Enhance Accessibility of Effective Ulcerative Colitis Treatment in Canada

The approval of UCERIS rectal aerosol foam was based on two pivotal clinical studies. In these studies, a significantly higher proportion of patients treated with UCERIS were in remission at Week 6 compared to those who received a placebo. The studies also showed that a higher proportion of patients in the UCERIS group had a rectal bleeding sub-score of 0 and an endoscopy sub-score of 0 or 1 at Week 6, indicating minimal disease activity.

The expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam signifies a significant step forward in making effective treatment options more accessible to Canadians suffering from mild to moderate distal ulcerative colitis. With these new listings, Bausch Health continues to demonstrate its commitment to enhancing patient access to innovative therapies, thereby improving health outcomes for individuals across the country.


You can follow our news on our Telegram and LinkedIn accounts.

Resource: Bausch Health Canada, May 23, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article